KalVista Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US4834971032

SecurityKALV / KalVista Pharmaceuticals, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Dimensional Fund Advisors Lp closes position in KALV / KalVista Pharmaceuticals, Inc.

On February 12, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 0 shares of KalVista Pharmaceuticals, Inc. (US:KALV) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 12, 2025 disclosing 45,444 shares of KalVista Pharmaceuticals, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -100.00 0
2025-11-12 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 45,444 -127,765 -73.76 554 -71.76 0.0000
2025-08-12 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 173,209 -472,784 -73.19 1,959 -73.74 0.0005
2025-05-13 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 645,993 -50,044 -7.19 7,455 26.46 0.0019
2025-02-13 2024-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 696,037 89,001 14.66 5,895 -16.16 0.0014
2024-11-07 2024-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 607,036 72,057 13.47 7,031 11.57 0.0017
2024-08-09 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 534,979 -44,680 -7.71 6,303 -8.32 0.0016
2024-05-10 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 579,659 -137,305 -19.15 6,875 -21.73 0.0019
2024-02-07 2023-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 716,964 134,059 23.00 8,783 56.46 0.0026
2023-11-09 2023-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 582,905 162,369 38.61 5,613 48.34 0.0018
2023-08-09 2023-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 420,536 184,269 77.99 3,785 103.88 0.0012
2023-05-12 2023-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 236,267 -27,600 -10.46 1,857 185,500.00 0.0006
2023-02-09 2022-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 263,867 -72,251 -21.50 2 -99.98 0.0005
2022-11-10 2022-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 336,118 71,640 27.09 4,876 87.32 0.0019
2022-08-12 2022-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 264,478 188,926 250.06 2,603 133.66 0.0009
2022-05-13 2022-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 75,552 -92,779 -55.12 1,114 -49.98 0.0003
2022-02-09 2021-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 168,331 -1,877 -1.10 2,227 -25.02 0.0007
2021-11-12 2021-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 170,208 0 0.00 2,970 -27.17 0.0010
2021-08-12 2021-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 170,208 -58,417 -25.55 4,078 -30.56 0.0013
2021-05-14 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 228,625 22,108 10.71 5,873 49.75 0.0019
2021-03-08 2020-12-31 13F/A-2 KALVISTA PHARMACEUTICALS COM 483497103 206,517 10,336 5.27 3,922 58.79 0.0014
2021-02-11 2020-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 206,517 10,336 3,922 1,416.4179
2020-11-12 2020-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 196,181 2,000 1.03 2,470 5.11 0.0010
2020-08-13 2020-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 194,181 25,339 15.01 2,350 81.89 0.0010
2020-05-14 2020-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 168,842 48,034 39.76 1,292 -39.93 0.0007
2020-02-14 2019-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 120,808 -7,682 -5.98 2,151 44.27 0.0008
2019-11-12 2019-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 128,490 16,860 15.10 1,491 -39.71 0.0006
2019-08-13 2019-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 111,630 39,083 53.87 2,473 19.12 0.0010
2019-08-12 2019-03-31 13F/A-2 KALVISTA PHARMACEUTICALS COM 483497103 72,547 61,414 551.64 2,076 843.64 0.0008
2019-05-10 2019-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 72,547 61,414 2,076
2019-02-26 2018-12-31 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 11,133 -1,250 -10.09 220 -19.71 0.0001
2019-02-13 2018-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 11,133 -1,250 220
2018-11-13 2018-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 12,383 12,383 274 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.